Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four <scp>JAK</scp> Inhibitors in Moderate‐To‐Severe Atopic Dermatitis

Among oral JAKis, upadacitinib 30 mg, followed by upadacitinib 15 mg, achieved the most consistent short-term efficacy, providing superior skin clearance and itch relief. Abrocitinib 200 mg and ivarmacitinib 8 mg showed intermediate benefits, whereas baricitinib displayed modest effects. These findings support a provisional efficacy preference for upadacitinib in managing moderate-to-severe AD unresponsive to biologic or topical therapies.